Theratechnologies Valuation
| TH Stock | CAD 1.74 0.06 3.57% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Theratechnologies has a current Real Value of C$1.47 per share. The regular price of the company is C$1.74. Our model measures the value of Theratechnologies from inspecting the company fundamentals such as Shares Outstanding of 45.98 M, operating margin of 0.27 %, and Return On Equity of -11.17 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Theratechnologies' valuation include:
Price Book 19.4616 | Enterprise Value 106.8 M | Enterprise Value Ebitda 6.5475 | Price Sales 0.9489 | Forward PE 17.7936 |
Overvalued
Today
Please note that Theratechnologies' price fluctuation is very risky at this time. Calculation of the real value of Theratechnologies is based on 3 months time horizon. Increasing Theratechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Theratechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Theratechnologies Stock. However, Theratechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.74 | Real 1.47 | Hype 1.74 | Naive 1.78 |
The intrinsic value of Theratechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Theratechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Theratechnologies helps investors to forecast how Theratechnologies stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Theratechnologies more accurately as focusing exclusively on Theratechnologies' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Theratechnologies' intrinsic value based on its ongoing forecasts of Theratechnologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Theratechnologies' closest peers.
Theratechnologies Cash |
|
Theratechnologies Valuation Trend
Knowing Theratechnologies' actual value is paramount for traders when making sound investment determinations. Using both Theratechnologies' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Theratechnologies Total Value Analysis
Theratechnologies is at this time anticipated to have takeover price of 106.76 M with market capitalization of 80.01 M, debt of 58.97 M, and cash on hands of 9.21 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Theratechnologies fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
106.76 M | 80.01 M | 58.97 M | 9.21 M |
Theratechnologies Investor Information
About 52.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.06. Theratechnologies last dividend was issued on the 18th of October 2000. The entity had 1:4 split on the 31st of July 2023. Based on the key indicators related to Theratechnologies' liquidity, profitability, solvency, and operating efficiency, Theratechnologies may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Theratechnologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Theratechnologies has an asset utilization ratio of 105.14 percent. This suggests that the Company is making C$1.05 for each dollar of assets. An increasing asset utilization means that Theratechnologies is more efficient with each dollar of assets it utilizes for everyday operations.Theratechnologies Ownership Allocation
Theratechnologies shows a total of 45.98 Million outstanding shares. Over half of Theratechnologies' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Theratechnologies. Please watch out for any change in the institutional holdings of Theratechnologies as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Theratechnologies Profitability Analysis
The company reported the revenue of 81.76 M. Net Loss for the year was (23.96 M) with profit before overhead, payroll, taxes, and interest of 56.22 M.About Theratechnologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Theratechnologies. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Theratechnologies based exclusively on its fundamental and basic technical indicators. By analyzing Theratechnologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Theratechnologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Theratechnologies. We calculate exposure to Theratechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Theratechnologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 71.4 M | 75 M | |
| Pretax Profit Margin | (0.26) | (0.27) | |
| Operating Profit Margin | (0.13) | (0.12) | |
| Net Loss | (0.26) | (0.28) | |
| Gross Profit Margin | 0.87 | 0.96 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.